Enanta Pharma (ENTA) Tops Q3 EPS by 4c. Revs Miss

Enanta Pharma (NASDAQ: ENTA) reported Q3 EPS of ($0.44), $0.04 better than the analyst estimate of ($0.48). Revenue for the quarter came in at $7.5 million versus the consensus estimate of $8.14 million.

For earnings history and earnings-related data on Enanta Pharma (ENTA) click here.

You May Also Be Interested In

• Lucid reports Q2 output, names new CFO and five other leaders
• Lindsay (LNN) Tops Q3 EPS by 18c, Misses on Revenue
• Tesla Q2 deliveries reach 480,126, topping estimates of 406,024